vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与GIBRALTAR INDUSTRIES, INC.（ROCK）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是GIBRALTAR INDUSTRIES, INC.的1.8倍（$406.6M vs $225.0M），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs 24.9%），BIOCRYST PHARMACEUTICALS INC自由现金流更多（$291.2M vs $26.2M），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs -12.3%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
直布罗陀工业公司是专业建筑、基础设施及可再生能源产品制造商与分销商，主营通风系统、屋面配件、太阳能安装支架、园林景观产品等，主要服务北美地区住宅、商业建筑及清洁能源市场，专注提供创新可持续的客户解决方案。
BCRX vs ROCK — 直观对比
营收规模更大
BCRX
是对方的1.8倍
$225.0M
营收增速更快
BCRX
高出184.1%
24.9%
自由现金流更多
BCRX
多$264.9M
$26.2M
两年增速更快
BCRX
近两年复合增速
-12.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $225.0M |
| 净利润 | $245.8M | — |
| 毛利率 | 97.7% | 25.3% |
| 营业利润率 | 64.0% | 7.9% |
| 净利率 | 60.5% | — |
| 营收同比 | 209.1% | 24.9% |
| 净利润同比 | 1017.5% | — |
| 每股收益（稀释后） | $1.13 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXROCK
| Q4 25 | $406.6M | $225.0M | ||
| Q3 25 | $159.4M | $310.9M | ||
| Q2 25 | $163.4M | $309.5M | ||
| Q1 25 | $145.5M | $290.0M | ||
| Q4 24 | $131.5M | $180.1M | ||
| Q3 24 | $117.1M | $277.1M | ||
| Q2 24 | $109.3M | $273.6M | ||
| Q1 24 | $92.8M | $292.5M |
净利润BCRXROCK
| Q4 25 | $245.8M | — | ||
| Q3 25 | $12.9M | $-89.1M | ||
| Q2 25 | $5.1M | $26.0M | ||
| Q1 25 | $32.0K | $21.1M | ||
| Q4 24 | $-26.8M | — | ||
| Q3 24 | $-14.0M | $34.0M | ||
| Q2 24 | $-12.7M | $32.2M | ||
| Q1 24 | $-35.4M | $24.9M |
毛利率BCRXROCK
| Q4 25 | 97.7% | 25.3% | ||
| Q3 25 | 98.6% | 26.6% | ||
| Q2 25 | 98.3% | 28.4% | ||
| Q1 25 | 96.9% | 26.8% | ||
| Q4 24 | 95.4% | 29.0% | ||
| Q3 24 | 97.3% | 29.4% | ||
| Q2 24 | 98.4% | 30.5% | ||
| Q1 24 | 98.6% | 28.9% |
营业利润率BCRXROCK
| Q4 25 | 64.0% | 7.9% | ||
| Q3 25 | 18.6% | 12.8% | ||
| Q2 25 | 18.2% | 12.8% | ||
| Q1 25 | 14.6% | 8.8% | ||
| Q4 24 | -3.4% | 13.3% | ||
| Q3 24 | 6.6% | 15.6% | ||
| Q2 24 | 8.0% | 14.9% | ||
| Q1 24 | -15.6% | 10.8% |
净利率BCRXROCK
| Q4 25 | 60.5% | — | ||
| Q3 25 | 8.1% | -28.6% | ||
| Q2 25 | 3.1% | 8.4% | ||
| Q1 25 | 0.0% | 7.3% | ||
| Q4 24 | -20.4% | — | ||
| Q3 24 | -12.0% | 12.3% | ||
| Q2 24 | -11.6% | 11.8% | ||
| Q1 24 | -38.1% | 8.5% |
每股收益（稀释后）BCRXROCK
| Q4 25 | $1.13 | — | ||
| Q3 25 | $0.06 | $-2.98 | ||
| Q2 25 | $0.02 | $0.87 | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | $-0.07 | $1.11 | ||
| Q2 24 | $-0.06 | $1.05 | ||
| Q1 24 | $-0.17 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $115.7M |
| 总债务越低越好 | — | $0 |
| 股东权益账面价值 | $-119.2M | $950.4M |
| 总资产 | $514.2M | $1.4B |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资BCRXROCK
| Q4 25 | $274.7M | $115.7M | ||
| Q3 25 | $212.9M | $89.4M | ||
| Q2 25 | $260.0M | $43.3M | ||
| Q1 25 | $295.1M | $25.1M | ||
| Q4 24 | $320.9M | $269.5M | ||
| Q3 24 | $96.8M | $228.9M | ||
| Q2 24 | $78.4M | $179.1M | ||
| Q1 24 | $84.3M | $146.7M |
总债务BCRXROCK
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
股东权益BCRXROCK
| Q4 25 | $-119.2M | $950.4M | ||
| Q3 25 | $-387.9M | $951.8M | ||
| Q2 25 | $-421.6M | $1.0B | ||
| Q1 25 | $-451.9M | $1.0B | ||
| Q4 24 | $-475.9M | $1.0B | ||
| Q3 24 | $-468.6M | $1.0B | ||
| Q2 24 | $-475.6M | $975.7M | ||
| Q1 24 | $-476.2M | $940.2M |
总资产BCRXROCK
| Q4 25 | $514.2M | $1.4B | ||
| Q3 25 | $446.4M | $1.4B | ||
| Q2 25 | $457.2M | $1.5B | ||
| Q1 25 | $480.0M | $1.4B | ||
| Q4 24 | $490.4M | $1.4B | ||
| Q3 24 | $491.3M | $1.4B | ||
| Q2 24 | $472.4M | $1.4B | ||
| Q1 24 | $467.9M | $1.3B |
负债/权益比BCRXROCK
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | $35.5M |
| 自由现金流经营现金流 - 资本支出 | $291.2M | $26.2M |
| 自由现金流率自由现金流/营收 | 71.6% | 11.7% |
| 资本支出强度资本支出/营收 | 0.2% | 4.1% |
| 现金转化率经营现金流/净利润 | 1.19× | — |
| 过去12个月自由现金流最近4个季度 | $344.9M | $120.6M |
8季度趋势，按日历期对齐
经营现金流BCRXROCK
| Q4 25 | $292.0M | $35.5M | ||
| Q3 25 | $41.6M | $73.0M | ||
| Q2 25 | $41.3M | $44.9M | ||
| Q1 25 | $-27.5M | $13.7M | ||
| Q4 24 | $-5.2M | $19.9M | ||
| Q3 24 | $8.2M | $64.7M | ||
| Q2 24 | $-1.4M | $36.5M | ||
| Q1 24 | $-53.7M | $53.2M |
自由现金流BCRXROCK
| Q4 25 | $291.2M | $26.2M | ||
| Q3 25 | $40.3M | $64.8M | ||
| Q2 25 | $41.1M | $27.3M | ||
| Q1 25 | $-27.7M | $2.3M | ||
| Q4 24 | $-5.9M | $14.1M | ||
| Q3 24 | $8.2M | $60.5M | ||
| Q2 24 | $-1.5M | $33.5M | ||
| Q1 24 | $-53.9M | $48.8M |
自由现金流率BCRXROCK
| Q4 25 | 71.6% | 11.7% | ||
| Q3 25 | 25.3% | 20.8% | ||
| Q2 25 | 25.2% | 8.8% | ||
| Q1 25 | -19.0% | 0.8% | ||
| Q4 24 | -4.5% | 7.8% | ||
| Q3 24 | 7.0% | 21.8% | ||
| Q2 24 | -1.4% | 12.2% | ||
| Q1 24 | -58.1% | 16.7% |
资本支出强度BCRXROCK
| Q4 25 | 0.2% | 4.1% | ||
| Q3 25 | 0.8% | 2.6% | ||
| Q2 25 | 0.1% | 5.7% | ||
| Q1 25 | 0.1% | 3.9% | ||
| Q4 24 | 0.5% | 3.3% | ||
| Q3 24 | 0.1% | 1.5% | ||
| Q2 24 | 0.1% | 1.1% | ||
| Q1 24 | 0.3% | 1.5% |
现金转化率BCRXROCK
| Q4 25 | 1.19× | — | ||
| Q3 25 | 3.23× | — | ||
| Q2 25 | 8.12× | 1.73× | ||
| Q1 25 | -859.91× | 0.65× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.13× | ||
| Q1 24 | — | 2.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
暂无分部数据
ROCK
| Transferred At Point In Time | $183.5M | 82% |
| Infrastructure | $22.5M | 10% |
| Other | $18.9M | 8% |
